Successfully Navigate Fragmented European Datasets, Establish Robust Integrated Evidence Plans & Enhance Real World Evidence Generation with AI to Improve Decision Making & Support Reimbursement Decisions
As regulators and payers increasingly elevated the importance of Real World Evidence in submission and reimbursement requirements, the EHDS regulation marked a landmark move towards data sharing, and as increasingly robust AI transformed big data analysis, it had never been more critical to harness RWE to uncover unmet needs, demonstrate treatment value beyond the clinical trial setting, and influence decision-making across regulators, payers, providers, and patients.
The 3rd IMPACCT Real World Evidence Summit Europe was the only industry meeting dedicated to uniting experts in RWE, Evidence Generation, and Medical Affairs to consolidate, innovate and apply RWE across the drug development lifecycle, from external control arms to reimbursement.
With a tight focus on leveraging AI for big data analysis, accessing standardised and high-quality datasets, and creating a robust integrated evidence strategy, 50+ industry pioneers from AstraZeneca, Pfizer, Novartis, Boehringer Ingelheim and more came together to collaboratively establish best practice and bridge the evidence gap between clinical research and practice.
Attending Companies Included